SEC Comment Letter for Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Nov 12, 2019
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: Nov. 12, 2019 · CIK: 0001213037 · Accession: 0000000000-19-015417
AI Filing Summary & Sentiment
File numbers found in text: 333-234442
Letter
November 12, 2019 Thomas H. Adams Chief Executive Officer Trovagene, Inc. 11055 Flintkote Avenue San Diego, CA 92121 Re:Trovagene, Inc. Registration Statement on Form S-1 Filed November 1, 2019 File No. 333-234442 Dear Mr. Adams: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Gregory Dundas, Attorney Adviser, at (202) 551-3436 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Fessler, Esq.
Show Raw Text
November 12, 2019
Thomas H. Adams
Chief Executive Officer
Trovagene, Inc.
11055 Flintkote Avenue
San Diego, CA 92121
Re:Trovagene, Inc.
Registration Statement on Form S-1
Filed November 1, 2019
File No. 333-234442
Dear Mr. Adams:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Gregory Dundas, Attorney Adviser, at (202) 551-3436 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Fessler, Esq.